Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.

ABSTRACT:

Objective

To analyze the association between pioglitazone use and bladder cancer through a spontaneous adverse event reporting system for medications.

Research design and methods

Case/noncase bladder cancer reports associated with antidiabetic drug use were retrieved from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) between 2004 and 2009 and analyzed by the reporting odds ratio (ROR).

Results

Ninety-three reports of bladder cancer were retrieved, corresponding to 138 drug-reaction pairs (pioglitazone, 31; insulin, 29; metformin, 25; glimepiride, 13; exenatide, 8; others, 22). ROR was indicative of a definite risk for pioglitazone (4.30 [95% CI 2.82-6.52]), and a much weaker risk for gliclazide and acarbose, with very few cases bein

SUBMITTER: Piccinni C 

PROVIDER: S-EPMC3114317 | biostudies-literature | 2011 Jun

REPOSITORIES: biostudies-literature